Hisco announced that on December 18, 2025, the company received the “Notice of Opinions from the Review Center on Hisilicon Pharmaceuticals Group Co., Ltd.'s Application to Issue Shares to Specific Targets” issued by the Shenzhen Stock Exchange Listing Review Center. The Shenzhen Stock Exchange Listing Review Center reviewed the application documents submitted by the company to issue shares to specific targets, and found that the company met the issuance conditions, listing conditions, and information disclosure requirements. The issue of the company's current issuance of shares to specific targets still needs to be approved by the China Securities Regulatory Commission for registration before it can be implemented.

Hisco announced that on December 18, 2025, the company received the “Notice of Opinions from the Review Center on Hisilicon Pharmaceuticals Group Co., Ltd.'s Application to Issue Shares to Specific Targets” issued by the Shenzhen Stock Exchange Listing Review Center. The Shenzhen Stock Exchange Listing Review Center reviewed the application documents submitted by the company to issue shares to specific targets, and found that the company met the issuance conditions, listing conditions, and information disclosure requirements. The issue of the company's current issuance of shares to specific targets still needs to be approved by the China Securities Regulatory Commission for registration before it can be implemented.